Mumbai, Aug. 13 -- The stake sale came two days after Catalyst Trusteeship, acting as debenture trustee, released the pledge on 1,75,00,000 Thyrocare shares, or 10.99% equity, held by Docon on 11 August 2026. The release reduced the number of encumbered shares but did not change Docon's overall shareholding in Thyrocare.

As of June 2026, Docon held 9,69,69,696 shares, representing a 60.92% stake in Thyrocare. Following the sale of 1,57,69,696 shares, its shareholding declined to 51.02% of the company's paid-up equity. Docon continues to remain a promoter and holding company of Thyrocare.

The shares sold were part of Docon's holding in Thyrocare. Docon had earlier pledged its entire 9,69,69,696-share holding as security for non-convertib...